Clinical Trial Update: YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access

View source ↗

Summary

This update reports that the single-patient compassionate use/expanded access program for Yondelis (trabectedin) in soft tissue sarcoma is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Yondelis (trabectedin)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Soft Tissue Sarcoma | Status: NO_LONGER_AVAILABLE